CSIMarket
 

Sight Sciences Inc   (SGHT)
Other Ticker:  
 

Sight Sciences Inc 's

Competitiveness


 

SGHT Sales vs. its Competitors Q3 2023







Revenue Growth Comparisons




Net Income Comparison




<<  SGHT Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Sight Sciences Inc Contracts

Groundbreaking Results from The ROMEO Study: OMNI Surgery Achieves Remarkable Pressure ...

Sight Sciences Announces Promising Results from The ROMEO Study: OMNI Shows Effective Reductions in Pressure and Medication Usage Across All Stages of GlaucomaIn an exciting development for glaucoma patients, Sight Sciences has recently announced the publication of a new analysis from The ROMEO Study, demonstrating significant reductions in intraocular pressure (IOP) and medication usage achieved through the use of their OMNI surgical system. The analysis, which was published in Clinical Ophthalmology, provides evidence that OMNI is just as effective at addressing advanced glaucoma as it is with mild and moderate cases.Glaucoma, often referred to as the silent thief of sight, is a chronic eye condition chara...

Large-Scale Study Shows the Effectiveness of Sight Sciences' OMNI Surgical System in Treating Glaucoma

Sight Sciences, a leading medical technology company, has recently published a groundbreaking study demonstrating the efficacy of their OMNI Surgical System in treating glaucoma. The study, which evaluated over 100,000 glaucoma patient eyes, compared the outcomes of three commonly used Minimally Invasive Glaucoma Surgery (MIGS) technologies in combination with cataract surgery and cataract surgery alone. The results indicate that the OMNI Surgical System not only effectively lowers intraocular pressure (IOP), but also reduces the need for IOP reducing medications over a period of two years.The MIGS Study: Evaluating Treatment Options for Glaucoma PatientsGlaucoma, a chronic eye condition characterized by inc...

Evolving Ophthalmic Care: OMNI Surgical System Proves Effective for Glaucoma, TearCare Technology Provides Relief for Dry Eye Disease

In a remarkable breakthrough for the field of ophthalmology, Sight Sciences showcased the remarkable results of their GEMINI Trial and the cross-over phase of the SAHARA RCT at the prestigious 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. This pivotal event marked the unveiling of the OMNI Surgical System's long-term efficacy in treating primary open-angle glaucoma, as well as the TearCare technology's potential as a primary treatment for dry eye disease. These groundbreaking advancements have the potential to revolutionize ophthalmic care and improve the quality of life for millions of patients worldwide.OMNI Surgical System: Revolutionizing Glaucoma TreatmentPrimary open-...





Who are Sight Sciences Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com